A study on the prevalence and prognosis of progressive pulmonary fibrosis: A retrospective observational study.

Medicine (Baltimore)

Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.

Published: May 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Interstitial lung disease (ILD) encompasses a heterogeneous group of more than 200 diffuse parenchymal lung diseases with various clinical courses. Disease progression is one of the most important prognostic factors, and, the definition of progressive pulmonary fibrosis (PPF) has recently been established. This study aimed to estimate the prevalence, risk factors, and prognosis of PPF among patients with non-idiopathic pulmonary fibrosis (IPF) in real-world practice. A total of 215 patients were retrospectively analyzed between January 2010 and June 2023 at the Haeundae Paik Hospital in the Republic of Korea. According to the criteria proposed in 2022 by Raghu et al, PPF defined as a condition that satisfies 2 or more of the following in the past year: worsening of respiratory symptoms, physiological evidence of disease progression, and radiological evidence of disease progression. The median age of the subjects was 67 years and 63.7% were female. A total of 40% was diagnosed with PPF and connective tissue disease-associated ILD (52.3%) was the most common type, followed by nonspecific interstitial pneumonitis (NSIP) (25.6%) and cryptogenic organizing pneumonitis (16.3%). In multivariate logistic regression for predicting PPF, both the use of steroids and immunosuppressants (OR: 2.57, 95% CI: 1.41-4.67, P = .002) and home oxygen use (OR: 25.17, 95% CI: 3.21-197.24, P = .002) were independent risk factors. During the follow-up period, the mortality rate was significantly higher in the PPF group than in the non-PPF group (24.4% vs 2.3%, P < .001). In the survival analysis using the Cox proportional hazard regression model, disease progression, older age and lower forced vital capacity (FVC) were independent risk factors for mortality. Our study demonstrated that the prevalence of PPF was 40%. Concomitant therapy of steroids with an immunosuppressants and home oxygen use are risk factors for PPF. PPF itself was significantly associated with high mortality rates. Risk factors for mortality were disease progression, older age, and lower FVC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11098177PMC
http://dx.doi.org/10.1097/MD.0000000000038226DOI Listing

Publication Analysis

Top Keywords

pulmonary fibrosis
12
disease progression
12
progressive pulmonary
8
risk factors
8
evidence disease
8
ppf
6
study prevalence
4
prevalence prognosis
4
prognosis progressive
4
fibrosis retrospective
4

Similar Publications

Recent improvements in cell-free DNA technology have enabled non-invasive prenatal testing (NIPT) to screen for fetal single-gene autosomal recessive conditions from maternal blood as early as the first trimester. This technique can determine the fetal risk for cystic fibrosis (CF) with a single blood sample from a pregnant person without the need for a partner sample, which is required for traditional carrier screening. A retrospective review of 100,106 consecutive general-risk pregnant patients who underwent CF carrier screening was completed.

View Article and Find Full Text PDF

Dual-sensitive gelatin-coated chitosan microparticles for targeted semaglutide pulmonary delivery: a novel approach to enhancing anti-inflammatory and anti-fibrotic effects.

Int Immunopharmacol

September 2025

Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah 51452, Saudi Arabia; Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt. Electronic address:

This study introduces a novel dual-sensitive drug delivery system, gelatin-coated chitosan microparticles (GL-ChMPs), designed to enhance the lung targeting and therapeutic efficacy of semaglutide (SEM). GL-ChMPs were designed to respond to the acidic environment and metalloproteinases, conditions that are typical in pulmonary fibrosis. SEM-GL-ChMPs exhibited superior lung targeting and prolonged retention while minimizing systemic distribution.

View Article and Find Full Text PDF

This study investigated the effects of Yttrium-90 (Y90) radioembolization in 8 rabbits, focusing on delivery accuracy, dosimetry, and pathological outcomes. Y90 was successfully delivered angiographically targeted via the pulmonary lower basal segmental arteries to all rabbits, with confirmation via PET/CT imaging and a lung target median of the mean dose 132.1Gy (range, 11.

View Article and Find Full Text PDF

Silicosis is a fatal occupational lung disease characterized by persistent inflammation and irreversible fibrosis. However, the pathogenesis of silicosis is currently unclear. In this study, a mouse model of silicosis was established by intranasal instillation of silica, and transcriptomic alterations in lung tissues were assessed by mRNA-sequencing.

View Article and Find Full Text PDF

Air pollution and diseases: signaling, G protein-coupled and Toll like receptors.

Pharmacol Ther

September 2025

Department of Molecular Pharmacology, University of Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, GRIAC, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address:

Air pollution is a significant public health issue that impacts lung health, particularly in vulnerable populations such as children, the elderly, and individuals with pre-existing respiratory conditions. Both natural and anthropogenic sources of air pollution give rise to a variety of toxic compounds, including particulate matter (PM), ozone (O₃), sulfur dioxide (SO₂), nitrogen dioxide (NO₂), carbon monoxide (CO), and polycyclic aromatic hydrocarbons (PAHs). Exposure to these pollutants is strongly associated with the development and exacerbation of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF).

View Article and Find Full Text PDF